Forecast
There is no analyst data available for this company.
Discussions in the community
There is no discussion about this asset yet.
Start discussionNews Go to news feed
PharmaSGP increases sales 15.4% to EUR 32.5m, earnings per share fall to EUR 0.29
PharmaSGP reported a sales rise of 15.41% to EUR 32.5m for the quarter to 30 June 2025 (previous year: EUR 28.2m). Earnings per share fell to EUR 0.29, compared with EUR 0.34 in the same quarter last year. » More on finanzen.net
PharmaSGP Holding SE announces delisting from the Frankfurt Stock Exchange as of August 11, 2025
PharmaSGP Holding SE will delist its shares from the Frankfurt Stock Exchange on August 11, 2025, following approval of the corresponding application. The delisting is related to a delisting acquisition offer by FUTRUE GmbH, with the acceptance period ending on the same day. PharmaSGP also plans to cease trading on other stock exchanges and to continue its growth strategy through expansion and M&A activities. » More on finanzen.net
PharmaSGP in focus after insider purchase by FUTRUE GmbH
PharmaSGP reported directors' dealings after FUTRUE GmbH acquired 6,670 shares at €28.00 each on July 23, 2025. The stock showed little price movement following the announcement and closed slightly lower at €28.40 on the day of the BaFin notification. FUTRUE GmbH had already significantly increased its stake in PharmaSGP in May. » More on finanzen.net
PharmaSGP Holding SE faces squeeze-out by FUTRUE GmbH
FUTRUE GmbH has informed PharmaSGP Holding SE that it holds over 95% of the shares and intends to initiate a squeeze-out of minority shareholders. The general meeting will decide on the transfer of the remaining shares in exchange for a cash settlement, the amount of which is yet to be determined. PharmaSGP also plans to further strengthen its market position through expansion and M&A activities. » More on finanzen.net
PharmaSGP significantly raises revenue forecast for 2025
PharmaSGP Holding SE has raised its revenue forecast for the 2025 financial year to between 132 and 138 million euros, up from the previous estimate of 122 to 128 million euros. The forecast for adjusted EBITDA remains unchanged at 37 to 39 million euros, resulting in a slightly lower EBITDA margin. The company points to ongoing uncertainties in the geopolitical and global economic environment. » More on finanzen.net
Historical dividends Dividends
All dividend metrics All metricsIn 2025, PHARMASGP HOLDING SE O.N. has already paid €0.05 in dividends. The last payout was in July 2025.
Financials
In the last year, PHARMASGP HOLDING SE O.N. had revenue of €118.84m and net profit of €19.54m
| (EUR) | 2024 | YoY |
|---|---|---|
| Revenue | 118.84m | 17.55% |
| Gross profit | 107.99m | 17.85% |
| Net profit | 19.54m | 19.14% |
| EBITDA | 39.6m | 10.39% |
Fundamentals
| Metric | Value |
|---|---|
Market capitalization | €333.86m |
Number of shares | 11.51m |
52-week high/low | €30.00 - €19.00 |
| Dividends | No |
Beta | -0.03 |
P/E ratio | 17.58 |
PEG ratio | 1.78 |
P/B ratio | 10.77 |
P/S ratio | 2.81 |
Company profile
PharmaSGP Holding SE manufactures over-the-counter drugs, and other healthcare products in Germany. The company's pharmaceutical products include Baldriparan for the treatment of sleep disorders; Spalt, Formigran, and Kamol massage cream for the treatment of different pain conditions; RubaXX pharmaceutical drops for the treatment of rheumatic pain in bones, tendons, and muscles; Restaxil pharmaceutical drops for the treatment of nerve pain in neck and back; Fulminan, a beauty drink for problems in areas, such as eye area, buttocks, or thighs; DESEO pharmaceutical drops for sexual weakness; Neradin, a drug for sexual dysfunction; and TAUMEA, a drug for the treatment of vertigo. It also offers products for the treatment of chronic indications, including pain and other age-related ailments. The company sells its products through pharmacies and wholesalers. It exports its products to European countries comprising Austria, Italy, Belgium, Spain, and France. The company was founded in 2012 and is based in Gräfelfing, Germany.
| Name | PHARMASGP HOLDING SE O.N. |
| CEO | Peter Gerckens |
| Headquarters | Gräfelfing,
Germany |
| Website | |
| IPO | 19/06/2020 |
| Employees | 91 |
Ticker symbols
| Exchange | Symbol |
|---|---|
XETRA | PSG.DE |
Frankfurt | PSG.F |
Düsseldorf | PSG.DU |
München | PSG.MU |